Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.

Xu X, Han L, Duan L, Zhao Y, Yang H, Zhou B, Ma R, Yuan R, Zhou H, Liu Z.

Br J Clin Pharmacol. 2013 Feb;75(2):516-23. doi: 10.1111/j.1365-2125.2012.04379.x.

PMID:
22804784
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.

Xu X, Ren H, Zhou B, Zhao Y, Yuan R, Ma R, Zhou H, Liu Z.

Lung Cancer. 2012 Aug;77(2):438-42. doi: 10.1016/j.lungcan.2012.03.023. Epub 2012 Apr 17.

PMID:
22516052
[PubMed - indexed for MEDLINE]
3.

Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.

Xu X, Duan L, Zhou B, Ma R, Zhou H, Liu Z.

Clin Exp Pharmacol Physiol. 2012 Sep;39(9):786-92. doi: 10.1111/j.1440-1681.2012.05741.x.

PMID:
22725681
[PubMed - indexed for MEDLINE]
4.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
[PubMed - indexed for MEDLINE]
5.

Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.

Zhang L, Gao G, Li X, Ren S, Li A, Xu J, Zhang J, Zhou C.

PLoS One. 2012;7(10):e48350. doi: 10.1371/journal.pone.0048350. Epub 2012 Oct 31.

PMID:
23118991
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.

He C, Duan Z, Li P, Xu Q, Yuan Y.

Anticancer Drugs. 2013 Mar;24(3):300-5. doi: 10.1097/CAD.0b013e32835bd6ce.

PMID:
23211354
[PubMed - indexed for MEDLINE]
7.

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X.

Lung Cancer. 2011 Jan;71(1):82-8. doi: 10.1016/j.lungcan.2010.04.008. Epub 2010 May 5.

PMID:
20447721
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.

Zhou F, Gao G, Ren S, Li X, He Y, Zhou C.

PLoS One. 2013 Apr 19;8(4):e61585. doi: 10.1371/journal.pone.0061585. Print 2013.

PMID:
23620771
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

Qian J, Qu HQ, Yang L, Yin M, Wang Q, Gu S, Wu Q, Zhao X, Wu W, Wu J, Tan X, Chen W, Wang H, Wang J, Fan W, Chen H, Han B, Lu D, Wei Q, Jin L.

Oncologist. 2012;17(12):1551-61. doi: 10.1634/theoncologist.2011-0419. Epub 2012 Jul 27.

PMID:
22843554
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.

Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.

Lung Cancer. 2012 Jan;75(1):102-9. doi: 10.1016/j.lungcan.2011.05.023. Epub 2011 Jun 14.

PMID:
21676483
[PubMed - indexed for MEDLINE]
11.

Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.

Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X.

Int J Hyg Environ Health. 2010 Mar;213(2):140-5. doi: 10.1016/j.ijheh.2010.01.004. Epub 2010 Mar 1.

PMID:
20189873
[PubMed - indexed for MEDLINE]
12.

The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.

Xu X, Han L, Yang H, Duan L, Zhou B, Zhao Y, Qu J, Ma R, Zhou H, Liu Z.

Lung Cancer. 2013 Jan;79(1):65-72. doi: 10.1016/j.lungcan.2012.10.005. Epub 2012 Nov 3.

PMID:
23127338
[PubMed - indexed for MEDLINE]
13.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.

Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.

PMID:
19157633
[PubMed - indexed for MEDLINE]
14.

[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].

Xu C, Wang X, Zhang Y, Li L.

Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):912-7. doi: 10.3779/j.issn.1009-3419.2011.12.03. Chinese.

PMID:
22152690
[PubMed - indexed for MEDLINE]
Free Article
15.

Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.

Am J Clin Oncol. 2010 Oct;33(5):489-94. doi: 10.1097/COC.0b013e3181b9cedc.

PMID:
20351547
[PubMed - indexed for MEDLINE]
16.

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.

PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.

PMID:
22479369
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.

Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y.

Cancer Chemother Pharmacol. 2013 May;71(5):1287-95. doi: 10.1007/s00280-013-2127-8. Epub 2013 Mar 12.

PMID:
23479135
[PubMed - indexed for MEDLINE]
18.

Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.

Zhao X, Wang X, Wu W, Gao Z, Wu J, Garfield DH, Wang H, Wang J, Qian J, Li H, Jin L, Li Q, Han B, Lu D, Bai C.

Cancer. 2012 Jul 15;118(14):3587-98. doi: 10.1002/cncr.26669. Epub 2011 Nov 9.

PMID:
22072145
[PubMed - indexed for MEDLINE]
Free Article
19.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.

Jpn J Clin Oncol. 2010 Oct;40(10):954-60. doi: 10.1093/jjco/hyq071. Epub 2010 May 12.

PMID:
20462983
[PubMed - indexed for MEDLINE]
Free Article
20.

Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.

Xu TP, Shen H, Liu LX, Shu YQ.

Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30.

PMID:
23727606
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk